Pabisstat API

Name	Pabisstat
Chinese name	帕比司他
Cas Number	404950-80-7
Source	India
Qualifications	USDMF/-/-/-/-

Pabirestat is a hydroxamic acid-based small molecule histone deacetylase (HDAC) inhibitor developed by Novartis. It was approved for marketing by the U.S. Food and Drug Administration (FDA) on February 23, 2015. Pabirestat is a new type of broad-spectrum histone deacetylase (HDAC) inhibitor with a new mechanism of action. By blocking histone deacetylase (HDAC), it can treat cancer cells Severe stress until its death, and healthy cells are not affected. Clinical studies have shown that Pabirestat has a positive effect on prolonging the survival time of patients with multiple myeloma, and brings new hope for the improvement of the quality of life of patients with advanced multiple myeloma. At present, there are many kinds of clinical anti-tumor drugs, but they all have more or less disadvantages such as limited curative effect and strong side effects. Pabirestat is an important anti-tumor drug based on epigenetics. Both solid tumor cells have inhibitory and killing effects, which can reduce the damage to normal tissues while ensuring high specificity and selectivity, and are expected to become ideal chemotherapy drugs. It is predicted that the global multiple myeloma treatment market will grow from USD 8.9 billion in 2014 to USD 22.4 billion in 2021.

Hot Tags: pabisstat api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Fulvestrant API, Vinpocetine API, Lurasidone Hydrochloride API, Lapatinib Ditosylate API, Deoxycholic Acid API, Fondaparinux API

• Previous: Opemifene API
• Next: Bilastine API